NLS Pharmaceutics Warrant
NLSPW
NLSPW was delisted on the 30th of October, 2025.
6 hedge funds and large institutions have $765K invested in NLS Pharmaceutics Warrant in 2021 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 6 → 6 (0)
12% less capital invested
Capital invested by funds: $874K → $765K (-$109K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
+$72 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$4.29K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$658 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $413K | – | – | – |
|
|
WVP
2
Worth Venture Partners
Fort Lee,
New Jersey
| $161K | – | – | – |
|
3
Hudson Bay Capital Management
Stamford,
Connecticut
| $154K | – | – | – |
|
|
WAM
4
Warberg Asset Management
Winnetka,
Illinois
| $29K | -$4.29K | -4,631 | -12% |
|
|
5
Bank Julius Baer & Co
Zurich,
Switzerland
| $6K | +$72 | +78 | +1% |
|
|
6
UBS Group
Zurich,
Switzerland
| $2K | -$658 | -711 | -21% |
|
NLSPW Hedge Fund Activity: Q3 2021 in Review
6 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in NLS Pharmaceutics Warrant (NLSPW) for Q3 2021, worth a combined $765K — down 12% from $874K a quarter earlier.
Fund positioning in NLSPW was balanced in Q3 2021: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was Bank Julius Baer & Co, adding an estimated $72. The largest seller was Warberg Asset Management, cutting an estimated $4.29K.
- 6 institutional investors held NLS Pharmaceutics Warrant (NLSPW) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $765K of NLS Pharmaceutics Warrant stock for Q3 2021, down 12% quarter-over-quarter.
- 0 funds opened new NLS Pharmaceutics Warrant positions in Q3 2021 and 0 closed out.
- The largest NLS Pharmaceutics Warrant buyer in Q3 2021 was Bank Julius Baer & Co, an estimated $72 added.
- The largest NLS Pharmaceutics Warrant seller in Q3 2021 was Warberg Asset Management, an estimated $4.29K sold.
Based on aggregated 13F filings for Q3 2021.